Filtros de búsqueda

Lista de obras de Herve Avet-Loiseau

14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia

artículo científico publicado en 2003

14q32 chromosomal translocations: a hallmark of plasma cell dyscrasias?

artículo científico publicado en 2000

8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma.

artículo científico publicado en 2013

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma

artículo científico publicado en 2016

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.

artículo científico publicado en 2016

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

artículo científico publicado en 2019

A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease

artículo científico publicado en 2003

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

artículo científico publicado en 2013

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

artículo científico publicado en 2010

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

scientific article published on 13 October 2009

Activating Ras mutations in patients with plasma-cell disorders: a reappraisal

scientific article published on 01 August 2002

Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas

scientific article published on 01 November 1996

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acu

artículo científico publicado en 2005

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

artículo científico publicado en 2014

Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation

artículo científico publicado en 2002

Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup

artículo científico publicado en 2003

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.

artículo científico publicado en 2017

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

artículo científico publicado en 2018

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice

artículo científico publicado en 2016

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

artículo científico publicado en 2017

Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

artículo científico publicado en 2012

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.

artículo científico publicado en 2017

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

artículo científico publicado en 2009

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

artículo científico publicado en 2010

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

artículo científico publicado en 2010

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

artículo científico publicado en 2011

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

artículo científico publicado en 2016

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

artículo científico publicado en 2003

CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target

scientific article published on 01 November 2005

CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique

artículo científico publicado en 2002

Ca2+-sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids.

artículo científico publicado en 2001

Carfilzomib Weekly 20/56mg/m , Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma

artículo científico publicado en 2018

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

artículo científico publicado en 2016

Circulating exosomal microRNA as biomarkers in mutiple myeloma

artículo científico publicado en 2017

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

artículo científico publicado en 2015

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

artículo científico publicado en 2012

Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas.

artículo científico publicado en 2002

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma

artículo científico

Construction of a 780-kb PAC, BAC, and cosmid contig encompassing the minimal critical deletion involved in B cell chronic lymphocytic leukemia at 13q14.3.

artículo científico publicado en 1997

Cyclin D1 expression in patients with multiple myeloma

artículo científico publicado en 2000

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience

artículo científico publicado en 2011

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

scholarly article by Andrew Spencer et al published 20 September 2018 in Haematologica

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

scholarly article by Athanasios Dimopoulos et al published 20 September 2018 in Haematologica

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

artículo científico publicado en 2013

Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization

artículo científico publicado en 1999

Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial.

artículo científico publicado en 2013

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.

artículo científico publicado en 2018

Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.

artículo científico publicado en 2013

Expressed fusion gene landscape and its impact in multiple myeloma.

artículo científico publicado en 2017

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.

artículo científico publicado en 2018

Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia

artículo científico publicado en 2000

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.

artículo científico publicado en 2018

Gene Expression Profiles in Myeloma: Ready for the Real World?

artículo científico publicado en 2016

Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.

artículo científico publicado en 2014

Gene signature combinations improve prognostic stratification of multiple myeloma patients.

artículo científico publicado en 2015

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

artículo científico publicado en 2007

Genetic heterogeneity in multiple myeloma.

artículo científico publicado en 2005

Genetics of multiple myeloma: another heterogeneity level?

artículo científico publicado en 2015

Genomic patterns of progression in smoldering multiple myeloma

scientific article published in Nature Communications

Genomics of Multiple Myeloma.

artículo científico publicado en 2017

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. ⬇️

artículo científico publicado en 2017

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria

artículo científico publicado en 2017

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

artículo científico publicado en 2007

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

artículo científico publicado en 2001

IMWG consensus on risk stratification in multiple myeloma

artículo científico

Identification of miRSNPs associated with the risk of multiple myeloma.

artículo científico publicado en 2016

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

scientific article published on 08 June 2018

IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.

artículo científico publicado en 2014

IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.

artículo científico publicado en 2016

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

artículo científico publicado en 2009

Introduction to a review series on advances in multiple myeloma

artículo científico publicado en 2018

Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients

artículo científico publicado en 2003

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

artículo científico publicado en 2017

Lack of CD27 in myeloma delineates different presentation and outcome

scientific article published on 01 January 2006

Large deletions 5' to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia

scientific article published on 01 September 2002

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

artículo científico publicado en 2012

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

artículo científico publicado en 2014

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

artículo científico publicado en 2017

Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level

scientific article published on 08 January 2004

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

artículo científico publicado en 2018

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

artículo científico publicado en 2012

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

artículo científico publicado en 2008

Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma

scientific article published on 01 November 2008

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

scientific article published on 27 July 2006

Management of treatment-emergent peripheral neuropathy in multiple myeloma.

artículo científico publicado en 2011

Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia

scientific article published on 15 November 2007

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.

artículo científico publicado en 2005

MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma

article

Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy

artículo científico publicado en 2017

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

artículo científico publicado en 2010

Multiple myeloma clonal evolution in homogeneously treated patients

artículo científico publicado en 2018

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

article

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow

artículo científico publicado en 2018

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique

article

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

artículo científico publicado en 2014

Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles.

artículo científico publicado en 2017

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

scientific article published on 01 December 2018

Nucleotide excision repair is a potential therapeutic target in multiple myeloma.

artículo científico publicado en 2017

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation

artículo científico publicado en 2002

Optimizing therapy for del(17p) multiple myeloma.

artículo científico publicado en 2017

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.

artículo científico publicado en 2004

Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease

artículo científico publicado en 2008

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

artículo científico publicado en 2014

Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma

artículo científico publicado en 2005

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

article

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Prognostic role of circulating exosomal miRNAs in multiple myeloma

artículo científico publicado en 2017

Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

artículo científico publicado en 2012

Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study

artículo científico publicado en 2006

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

artículo científico publicado en 2017

Radiolabelling rituximab with (99m)Tc in three steps procedure

artículo científico publicado en 2015

Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization.

artículo científico publicado en 2015

Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications

artículo científico publicado en 2007

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

scientific article published on 01 September 2002

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside

artículo científico publicado en 2018

Rituximab in CD20 positive multiple myeloma

scientific article published on 01 February 2007

Rothmund-Thomson syndrome and osteosarcoma

scientific article published on 01 June 1996

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

artículo científico publicado en 2016

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

artículo científico publicado en 2018

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases

artículo científico publicado en 2008

Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.

artículo científico publicado en 2010

Stem cell transplantation in multiple myeloma

artículo científico publicado en 2007

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma

artículo científico publicado en 2018

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

artículo científico publicado en 2017

The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.

artículo científico publicado en 2007

The dChip survival analysis module for microarray data.

artículo científico publicado en 2011

Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

artículo científico publicado en 2005

Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants

artículo científico publicado en 2002

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

artículo científico publicado en 2010

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

artículo científico

Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature.

artículo científico

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)

scientific article published on 14 November 2018

[Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival]

scientific article published on 25 May 2007

[Malignant transformation of monoclonal gammopathy of undetermined significance]

scientific article published on 16 May 2007

t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma

scientific article published on 01 October 2003

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda